» Authors » M S Bayliss

M S Bayliss

Explore the profile of M S Bayliss including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 1406
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Kosinski M, Bayliss M, Bjorner J, Ware Jr J, Garber W, Batenhorst A, et al.
Qual Life Res . 2003 Dec; 12(8):963-74. PMID: 14651415
Background: Migraine and other severe headaches can cause suffering and reduce functioning and productivity. Patients are the best source of information about such impact. Objective: To develop a new short...
2.
Bayliss M, Dewey J, Dunlap I, Batenhorst A, Cady R, Diamond M, et al.
Qual Life Res . 2003 Dec; 12(8):953-61. PMID: 14651414
Background: Headache impact test (HIT) is a precise, practical tool that quantifies the impact of headache on respondents' lives. It is the first widely-available dynamic health assessment (DynHA). Applications of...
3.
McHutchison J, Ware Jr J, Bayliss M, Pianko S, Albrecht J, Cort S, et al.
J Hepatol . 2001 Feb; 34(1):140-7. PMID: 11211891
Background/aims: Interferon plus ribavirin is the most effective therapy for chronic hepatitis C. The aim of this study was to evaluate the effect of chronic hepatitis C and therapy on...
4.
Bayliss M, Espindle D, Buchner D, Blaiss M, Ware J
Qual Life Res . 2000 Dec; 9(4):451-66. PMID: 11131937
Background: Asthma treatment has broadened from managing clinical markers to incorporate factors that are most meaningful to patients, collectively called health-related quality of life (HQL). Objective: To develop an asthma-specific...
5.
Graham D, Blaiss M, Bayliss M, Espindle D, Ware Jr J
Allergy Asthma Proc . 2000 Jul; 21(3):151-8. PMID: 10892517
The goals of asthma treatment have broadened beyond managing traditional clinical markers of disease severity, and now include a focus on benefits of treatment in terms that are most meaningful...
6.
Ware Jr J, Bayliss M, Mannocchia M, Davis G
Hepatology . 1999 Jul; 30(2):550-5. PMID: 10421667
Hepatitis C infects nearly 4 million Americans. Most have chronic hepatitis C (CHC), which progresses to cirrhosis in about 20% of patients. Interferon treatment leads to transient responses in about...
7.
Bayliss M
Hepatology . 1999 Jul; 29(6 Suppl):3S-6S. PMID: 10386074
The health care system in the United States is at a turning point. We are experiencing a shift in focus from structure and process to outcomes, and from specific clinical...
8.
Neary M, Cort S, Bayliss M, Ware Jr J
Semin Liver Dis . 1999 Jun; 19 Suppl 1:77-85. PMID: 10349695
Although evidence of virologic elimination, normalization of serum alanine aminotransferase levels, and reduction in liver inflammation are the principal therapeutic outcome goals in chronic hepatitis C patients, improvement in health-related...
9.
Bayliss M, Gandek B, Bungay K, Sugano D, Hsu M, Ware Jr J
Qual Life Res . 1998 Mar; 7(1):39-55. PMID: 9481150
A 69-item questionnaire measuring generic functioning and well-being and disease-specific health outcomes was developed and tested using the pre-treatment data from patients with chronic hepatitis C (CHC) participating in two...
10.
Keller S, Bayliss M, Ware Jr J, Hsu M, Damiano A, Goss T
Health Serv Res . 1997 Aug; 32(3):367-84. PMID: 9240286
Objective: To compare the measurement properties of acute (one-week recall) and standard (four-week recall) versions of SF-36 Health Survey (SF-36) scale scores. Data Sources: SF-36 data collected from 142 participants...